Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics

<p>Abstract</p> <p>Background</p> <p>Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both...

Full description

Bibliographic Details
Main Authors:	Wilken Jason A, Webster Kristy T, Maihle Nita J
Format:	Article
Language:	English
Published:	BMC 2010-03-01
Series:	Journal of Ovarian Research
Online Access:	http://www.ovarianresearch.com/content/3/1/7

Similar Items

EGFR isoforms and gene regulation in human endometrial cancer cells
by: Maihle Nita J, et al.
Published: (2010-06-01)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
by: Ibrahim Sadek, et al.
Published: (2017-09-01)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
by: Wu YF, et al.
Published: (2015-09-01)

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
by: Marta Llaurado Fernandez, et al.
Published: (2019-01-01)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
by: Silvia La Monica, et al.
Published: (2017-12-01)

Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells
by: Wookyeom Yang, et al.
Published: (2021-05-01)

EGFR Rearrangements as Oncogenic Drivers and Therapeutic Targets in Lung Cancer
by: Gallant, Jean-Nicolas
Published: (2017)

Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors
by: Kenny Chitcholtan, et al.
Published: (2020-03-01)

Novel therapeutic strategies for targeting EGFR mutated non-small cell lung cancer
by: Drobnitzky, Neele
Published: (2017)

EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2019-11-01)

Pathogenesis and New Therapeutic Targets of Ovarian Cancer
by: Ie-Ming Shih, et al.
Published: (2012-01-01)

Therapeutic Targeting of Collective Invasion in Ovarian Cancer
by: Laura Moffitt, et al.
Published: (2019-03-01)

Target Points in Trastuzumab Resistance
by: Sahar Shojaei, et al.
Published: (2012-01-01)

In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
by: Christel Larbouret, et al.
Published: (2012-02-01)

Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.
by: Michael P Stany, et al.
Published: (2011-01-01)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
by: Martin Sattler, et al.
Published: (2008-01-01)

Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells
by: Heejin Lee, et al.
Published: (2020-03-01)

Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting
by: Xingyue Zong, et al.
Published: (2019-07-01)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
by: Laure Thouvenin, et al.
Published: (2021-08-01)

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
by: Arik Durcker, et al.
Published: (2020-10-01)

Enhancement of in vitro therapeutic efficacy using combination paclitaxel and ceramide therapy using EGFR targeted biodegradable polymeric nanoparticles in ovarian cancer model
Published: ()

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
by: Sangah Lee, et al.
Published: (2021-06-01)

Purinergic signalling pathway: therapeutic target in ovarian cancer
by: Nisha Chandran, et al.
Published: (2020-06-01)

An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer
by: Elena Alexandrova, et al.
Published: (2020-06-01)

A Current Review of Targeted Therapeutics for Ovarian Cancer
by: Susana M. Campos, et al.
Published: (2010-01-01)

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks
by: German G. Gomez, et al.
Published: (2013-12-01)

Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
by: Arik Drucker, et al.
Published: (2020-10-01)

Study of Molecular Mechanisms of Sensitivity and Resistance to EGFR-Targeted Therapy in Lung Cancer
by: Zhang, Zhenfeng
Published: (2010)

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
by: Dennis J. Slamon, et al.
Published: (2013-02-01)

Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
by: Patricia L Theard, et al.
Published: (2020-09-01)

Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
by: Xiao-Feng Le, et al.
Published: (2012-01-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

Targeting EGFR in Esophagogastric Cancer
by: Steven B. Maron, et al.
Published: (2020-12-01)

Fucose-containing fraction of Reishi in combination with trastuzumab for treatment of trastuzumab resistance human breast cancer cells
by: Jia-Jung Hsu, et al.
Published: (2012)

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
by: Jason T Fong, et al.
Published: (2013-01-01)

Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
by: Tsukuru Amano, et al.
Published: (2021-01-01)

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
by: Swenerton Kenneth D, et al.
Published: (2009-12-01)

Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor.
by: Young Pil Kim, et al.
Published: (2014-01-01)

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
by: Kaipeng Xie, et al.
Published: (2019-01-01)

Histones and their modifications in ovarian cancer – drivers of disease and therapeutic targets
by: Deborah Joy Marsh, et al.
Published: (2014-06-01)

Cannot write session to /tmp/vufind_sessions/sess_s1uejamh35sbmp8ffvcmolip8i